Jack Van Hyler

Dr. Jack Van Hyler

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2025 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
JHJack Van Hyler
Jack Van Hyler
KSKyle Singerman
Kyle Singerman
FSFrank A. De Stefano
Frank A. De Stefano
SKShannon M. Kraft
Shannon M. Kraft
HKHannah Kavookjian
Hannah Kavookjian

14 June 2026 in Audiology Research
Verified
Journal Article
Open access
PDF file
MMMatthew Mavandi
Matthew Mavandi
JHJack Van Hyler
Jack Van Hyler
ELEric Lee
Eric Lee
RSRamanjot Singh
Ramanjot Singh
DSDe Wet Swanepoel
De Wet Swanepoel
Vinaya ManchaiahVinaya Manchaiah
Vinaya Manchaiah
Background/Objectives: Sensorineural hearing loss (SNHL) is a chronic condition with no established pharmacological treatment. Recent advances in drug-based therapies offer promising opportunities to prevent or treat SNHL. This scoping review summarizes the current landscape of pharmacotherapeutics for SNHL. Methods: This scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). A literature search of PubMed, Google Scholar, Embase, Scopus, and Web of Science was conducted in 2024 using keywords related to SNHL and pharmacotherapeutics. A review protocol was preregistered on the Open Science Framework. A systematic search of five electronic databases identified published studies from 2004 to 2024 on pharmacological treatments for SNHL in human participants, as well as ongoing clinical trials. Interventions were categorized by mechanism of action: antioxidant therapy, steroid-based combination therapy, hematologic-based therapy, pathway modulator therapy, regenerative therapy, and gene therapy. A narrative synthesis approach was used to map key trends across treatment types, study designs, and outcomes. Results: Sixty-six records met the inclusion criteria, including 48 published studies and 18 ongoing or recently completed clinical trial records. Antioxidants, corticosteroids, hematologic agents, and pathway modulators have demonstrated potential in preventing or treating SNHL caused by cisplatin, aminoglycosides, noise-induced ototoxicity, and intraoperative cochlear implantation trauma. Emerging regenerative and gene therapies show promise as future pharmacologic treatment options. Conclusions: Pharmacologic therapies for SNHL are promising but remain constrained by small sample sizes, heterogeneous study designs, and drug delivery challenges across the blood–labyrinth barrier. Future research should prioritize multicenter randomized trials, optimized delivery strategies, and integration of precision medicine approaches.

28 July 2026 in Anatomia
Verified
Journal Article
Open access
PDF file
JHJack Van Hyler
Jack Van Hyler
JWJanice Wang
Janice Wang
PJPaige Elizabeth Johnson
Paige Elizabeth Johnson
KSKyle Singerman
Kyle Singerman
JBJason Brown
Jason Brown
SSSara Sloan
Sara Sloan
Background/Objectives: Ansa-cervicalis-to-recurrent laryngeal nerve (ARA) anastomosis is an established reinnervation procedure for unilateral vocal fold paralysis (UVFP). Successful surgery requires reliable identification of the ansa cervicalis motor entry point and the recurrent laryngeal nerve (RLN) laryngeal entry point to facilitate tension-free anastomosis while avoiding neurovascular injury. Their positions relative to a single palpable external landmark have not been quantified. Methods: Thirty-two ansa cervicales and corresponding RLNs were dissected from 23 formalin-embalmed cadavers. Mediolateral and superoinferior distances from each nerve entry point to the inferior border of the thyroid cartilage at the midline laryngeal prominence were measured and combined into a Euclidean landmark-referenced straight-line distance. Ansa cervicalis root lengths and branching patterns were also documented. Results: The mean straight-line distance was 43.3 mm (SD 9.7) for the ansa cervicalis and 55.5 mm (SD 11.7) for the RLN laryngeal entry point. The paired analysis mean difference in landmark-referenced straight-line distance was 12.2 mm (95% CI 8.3–16.0; p < 0.001), driven primarily by a mediolateral difference of 13.6 mm (p < 0.001). Mean lengths were 34.7 mm for the superior root, 38.6 mm for the inferior root, and 42.6 mm for main branch. No statistically significant differences were detected by sex or laterality. A three-root variant was observed in 6.25% of cases. Conclusions: The RLN laryngeal entry point is about 12 mm farther from the shared landmark than the ansa cervicalis motor entry point, with the difference primarily attributable to mediolateral position. This relationship may warrant intraoperative evaluation as a supplemental spatial reference during ARA dissection.